Login / Signup

Delving into the Therapeutic Potential of Carica papaya Leaf against Thrombocytopenia.

Seemal MunirZhi-Wei LiuTayyaba TariqRoshina RabailPrzemysław Łukasz KowalczewskiJacek LewandowiczAndrzej BlecharczykMuhammad AbidMuhammad Inam-Ur-RaheemRana Muhammad Bilal
Published in: Molecules (Basel, Switzerland) (2022)
Thrombocytopenia is a clinical manifestation that refers to the low platelet count, i.e., <150 × 10 3 /μL, of blood, resulting in imbalanced hemostasis, which leads to several fatal complications. The causative factors vary greatly, but, as a consequence, they interfere with platelet production and promote destruction, leading to death. Carica papaya leaf has unique therapeutic and medicinal characteristics against thrombocytopenia, and this is supported by scientific studies. Secondary metabolites and minerals in the leaf, such as carpaine and quercetin, promote platelet production, inhibit platelet destruction, and maintain platelet membrane through gene expression activity and the ceasing of viral proteases, respectively. This review explores the scientific studies that support the role of papaya leaf in the form of juice, extract, or powder against thrombocytopenia through animal modeling and clinical trials. Phytochemical profiles of C. papaya leaf revealed the presence of flavonoids, alkaloids, phenols, cardiac glycosides, tannins, terpenes, and saponins, which impart therapeutic potential to the leaf. The therapeutic benefits of the leaf include immunomodulatory, antiviral, antidiabetic, anticancer, antimalarial, antiangiogenic, antibacterial, and antioxidant activities. Several conducted scientific research studies have proved the efficacy of C. papaya leaf against thrombocytopenia, expanding the implication of natural sources to eradicate numerous ailments.
Keyphrases
  • gene expression
  • clinical trial
  • oxidative stress
  • heart failure
  • sars cov
  • risk factors
  • ms ms
  • randomized controlled trial
  • left ventricular
  • drinking water
  • study protocol
  • double blind
  • phase iii